"We are excited by the FDA's decision to approve Epi proColon as the first and only blood-based colorectal cancer screening test," Epigenomics CEO and CFO Thomas Taapken said in a statement.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.